Docket No. 0591-1010 Appln. No. 10/589,863

AMENDMENTS TO THE SPECIFICATION:

Please insert the following heading on page 1, between lines 2 and 3:

--FIELD OF THE INVENTION--

Please insert the following heading on page 1, between lines 10 and 11:

--BACKGROUND OF THE INVENTION--

Please replace the paragraph on page 2, beginning on line 18, with the following re-written paragraph:

--SUMMARY OF THE INVENTION

However, in <u>In</u> a quite surprising and unexpected way, the inventors have shown a therapeutic activity and, more specifically, a dermatological and cosmetic activity of these UCP proteins and/or these polypeptide or peptide fragments, particularly when these peptides and/or these peptide fragments are applied to the skin.—

Please insert the following heading on page 3, between lines 8 and 9:

--DETAILED DESCRIPTION OF THE INVENTION--

Docket No. 0591-1010 Appln. No. 10/589,863

Please replace the paragraph on page 3, beginning on line 9, with the following re-written paragraph:

--Preferentially according to the invention, the peptide fragments are peptides of formula (I):

wherein:

X1 = Leu, Thr, Val;

X2 = Asp, Glu;

X3 = Ala, Val;

X4 = Leu, Phe, Tyr;

X5 = Gln, Ile, Met;

and where (AA) is any particular amino acid or one of its derivatives, and n is a whole number ranging from 0 to 2.--

Please replace the paragraph on page 8, beginning on line 20, with the following re-written paragraph:

--In an advantageous way the composition according to the invention contains one or more peptides chosen among peptides corresponding to sequences ID N° (1) to ID N° (9) SEQ ID NO:1 to SEQ ID NO:9. According to a particularly advantageous embodiment of the invention, the composition contains the peptide of sequence Pro-Leu-Asp-Thr-Ala-Lys-Val-Arg-Leu-Gln (SEQ ID NO:1).

In a more general way, the composition, according to the invention, contains the active compound previously defined.--

Please replace the paragraph on page 12, beginning on line 29, with the following re-written paragraph:

- --3T3-L1 cells, seeded in 8-well Lab-Teks, were treated with the peptide of sequence ID N°(1) SEQ ID NO:1, i.e. of sequence Pro-Leu-Asp-Thr-Ala-Lys-Val-Arg-Leu-Gln, representative of the peptide family according to the invention, placed in a 0.5% solution at 50 ppm. The active ingredient was added at various stages of culture:
- At the start of the incubation and until the end of adipocyte differentiation (72 hours of culture until 100% confluence, then for the 6 days of differentiation);
- 6 hours after incubation and until the end of cell differentiation (66 hours of culture until 100% confluence, then for the 6 days of differentiation);
- Once cells differentiated in the adipocytes, they were treated with the active ingredient for 6, 24, or 48 hours.--

Please replace the paragraph on page 15, beginning on line 13, with the following re-written paragraph:

--Differentiated 3T3-L1 cells were treated with a 0.5% solution at 50 ppm, containing the peptide of sequence ID N $^{\circ}$ (1) SEQ ID NO:1, representative of the peptide family according to

the invention, for periods of 1 h 30, 3 h, 5 h, 7 h and 24 h.--

Please replace the Example beginning on page 17, beginning with line 1 and the entire table, with the following re-written paragraph and table:

-- **Example 2** - Preparation of compositions.

1. Slimming Cream

Commercial Names	INCI Names	% mass	
PHASE A			
Montanov 68	Cetearyl Alcohol (and) Cetearyl	5.00	
MONTANOV 68®	Glucoside		
Squalane	Squalane	2.50	
DUB IPP	Isopropyl Palmitate	3.50	
Eutanol-G-EUTANOL G®	Octyldodecanol	1.50	
Phenonip PHENONIP®	Phenoxyethanol (and)	0.50	
	Methylparaben (and) Ethylparaben (and)		
	Butylparaben (and) Propylparaben (and)		
	Isobutylparaben		
PHASE B	,		
Demineralized water	Aqua (Toilets)	qs	
Glycerine	Glycerin	3.00	
Butylene Glycol	Butylene glycol	3.00	
PHASE C			
Simulgel EG SIMULGEL EG®	Sodium Acrylate/Acryloyldimethyl	0.60	

	Taurate Copolymer (and) Isohexadecane (and) Polysorbate 80	
PHASE D		
Peptide ID N°(1) SEQ ID NO:1		1.25 ppm
Perfume	Perfume (Fragrance)	qs
Colorant		qs

__

Please replace the Table beginning on page 18, line 7, with the following re-written Table:

--2. Firming - Slimming Spray

Commercial Names	INCI Names	% mass
PHASE A		
Emulgade SEV	Glyceryl Stearate (and) Ceteareth-20	4.60
EMULGADE SEV®	(and) Ceteareth-12 (and) Cetearyl Alcohol	
Eumulgin B2 EUMULGIN B2®	Ceteareth-20	1.40
Cetiol OE CETIOL OE®	Dicaprylyl Ether	3.00
DUB B1215	C12-C15 Alkyl Benzoate	5.00
Phenonip-PHENONIP®	Phenoxyethanol (and) Methylparaben	0.50
	(and) Ethylparaben (and) Butylparaben	
	(and) Propylparaben (and) Isobutylparaben	
DUB ININ	Isononyl Isononanoate	5.00
Phenonip-PHENONIP®	Phenoxyethanol (and) Methylparaben	0.50
	(and) Ethylparaben (and) Butylparaben	
	(and) Propylparaben (and) Isobutylparaben	
PHASE B		
Demineralized water	Aqua (Toilets)	15.00

Commercial Names	INCI Names	% mass	
Glycerine	Glycerin	3.00	
PHASE C			
Demineralized water	Aqua (Toilets)	qs	
PHASE D		1	
Peptide ID N°(1) <u>SEQ ID NO:1</u>		1.50 ppm	
Perfume	Perfume (Fragrance)	qs	
Colorant		qs	

__

Please replace the Table beginning on page 19, line 8, with the following re-written Table:

--3. Firming - Slimming - Anti-Cellulite Gel

Commercial Names	INCI Names	% mass
Carbopol Ultrez 10 (2%)	Carbomer	25.00
CARBOPOL ULTREZ® 10 (2%)		
Demineralized water	Aqua (Toilets)	qs
DUB DIOL	Methyl Propanediol	3.00
EDTA	Tetrasodium EDTA	0.10
Glydant Plus Liquid	DMDM Hydantoïn (and)	0.20
	Iodopropynyl butylcarbamate	
Peptide ID N°(1) SEQ ID NO:1		1.25 ppm
TEA	Triethanolamine	0.50
Perfume	Perfume (Fragrance)	qs
Water-soluble colorant		qs
